Kenvue Inc.
KVUE
$17.14
-1.38%
Kenvue Inc. is the world's largest pure-play consumer health company, operating in the Household & Personal Products industry. It is a recent spin-off from Johnson & Johnson, defined by its portfolio of iconic brands like Tylenol and Neutrogena, and is pending acquisition by Kimberly-Clark.…
KVUE
Kenvue Inc.
$17.14
Related headlines
Investment Opinion: Should I buy KVUE Today?
Based on a synthesis of the data, the objective assessment is a Hold. The pending acquisition creates a unique situation where the stock's fate is largely tied to the deal's successful closure at an unspecified price. The company's solid fundamentals (strong brands, cash flow) are counterbalanced by low growth and valuation that is fair but not compelling (Forward P/E 14.24). For existing shareholders, holding for the deal closure is reasonable. For new investors, the limited upside potential and event-driven nature reduce the attractiveness of establishing a new position.
Sign up to view all
KVUE 12-Month Price Forecast
The investment thesis is overwhelmingly event-driven. The base case is a holding pattern until the acquisition closes. The low beta and defensive business provide some downside cushion, but the 12-month return is likely capped.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue Inc.'s 12-month outlook, with a consensus price target around $22.28 and implied upside of +30.0% versus the current price.
Average Target
$22.28
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$14 - $22
Analyst target range
No sufficient analyst coverage available. The provided data includes recent analyst rating actions from firms like Barclays and Citigroup, which are predominantly 'Hold' or 'Neutral', but does not include consensus target price or ratings distribution figures required for a summary.
Bulls vs Bears: KVUE Investment Factors
Kenvue presents a classic case of stability versus stagnation. Its powerful brands and strong cash generation are offset by minimal growth and recent stock underperformance. The pending acquisition by Kimberly-Clark is the dominant near-term factor, capping upside but providing a potential safety net.
Bullish
- Iconic Brand Portfolio: Owns leading consumer health brands like Tylenol and Neutrogena, providing stable revenue.
- Strong Free Cash Flow: Generates $1.72B in TTM free cash flow, supporting operations and potential returns.
- Pending Acquisition Premium: Agreed to be acquired by Kimberly-Clark, providing a potential floor and exit catalyst.
- Attractive Forward Valuation: Forward P/E of 14.24 is reasonable for a stable, cash-generative business.
Bearish
- Modest Growth Profile: Q4 revenue grew only 3.2% YoY, indicating limited organic expansion.
- Weak Liquidity Position: Current ratio of 0.96 signals potential short-term liquidity constraints.
- Post-IPO Volatility & Underperformance: Stock down 28% over past year, significantly underperforming the S&P 500.
- Acquisition Deal Uncertainty: Pending deal with Kimberly-Clark carries regulatory and execution risks until close.
KVUE Technical Analysis
The stock's overall trend has been volatile but positive over the last six months, rising 9.6% from October 2025 to March 2026. It reached a recent peak of $19.12 in late February before pulling back. In the short term, the stock has declined 9.83% over the past month, underperforming the S&P 500's 5.25% drop. However, it has shown relative strength over the past three months, posting a slight decline of 0.058% compared to the S&P 500's 4.63% fall. The current price of $17.24 sits near the middle of its 52-week range ($14.02 to $25.17), approximately 31% above the low and 31% below the high, indicating a neutral position after the recent correction.
Beta
0.47
0.47x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$14-$25
Price range past year
Annual Return
-28.2%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -5.6% | -3.6% |
| 3m | -1.0% | -4.0% |
| 6m | +8.4% | -2.0% |
| 1y | -28.2% | +16.2% |
| ytd | -1.0% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Revenue growth has been modest, with Q4 2025 revenue of $3.78 billion representing a 3.22% year-over-year increase. Profitability has been stable, with a net margin of 8.7% in Q4 2025, though it has fluctuated quarter-to-quarter from a low of 1.45% in Q2 2024 to highs near 11%. The company maintains a moderate debt-to-equity ratio of 0.79 and generates substantial free cash flow, with a trailing twelve-month figure of $1.72 billion. Operational efficiency is adequate, with a Return on Equity (ROE) of 13.66% and a Return on Assets (ROA) of 6.61%, though the current ratio of 0.96 indicates a tight liquidity position.
Quarterly Revenue
$3.8B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.56%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 22.42, while the forward P/E is lower at 14.24, suggesting expectations of earnings growth. The Price-to-Sales (P/S) ratio is 2.18 and the Enterprise Value-to-Sales (EV/Sales) is 2.69. Data for a direct peer comparison within the Household & Personal Products industry is not available in the provided inputs.
PE
22.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 20x~148x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is deal completion. The acquisition by Kimberly-Clark, expected in H2 2026, faces regulatory scrutiny and execution risk. If the deal fails, the stock could re-rate sharply lower based on its standalone modest growth and high trailing P/E. Financial risks include a tight liquidity position (current ratio 0.96) and fluctuating quarterly margins, as seen from a low of 1.45% to over 11%. Market risks are evident in the stock's high volatility (beta 0.47 suggests low correlation but stock has 42% max drawdown) and significant underperformance versus the broader market over the past year. Litigation and brand-related reputational risks, as hinted in recent news, are perennial concerns for a consumer health company.
FAQ
The paramount risk is the potential failure or delay of the Kimberly-Clark acquisition, which could cause a significant price drop. Financial risks include tight liquidity (current ratio 0.96) and fluctuating profit margins. Market risk is evident in the stock's 28% decline over the past year and high volatility relative to its beta. Ongoing product litigation and brand reputation are also constant sector risks.
The 12-month forecast is heavily influenced by the acquisition. The base case (60% probability) sees the stock trading between $17 and $20, reflecting deal uncertainty and modest fundamentals. The bull case (30%) targets $22-$25 on a successful deal closure. The bear case (10%) could see a drop to $14-$16 if the deal faces major issues. Consensus analyst estimates point to EPS of ~$1.29.
KVUE appears fairly valued. Its trailing P/E of 22.42 seems high for its growth profile, but the more relevant forward P/E of 14.24 is reasonable for a stable consumer health company. The Price-to-Sales ratio of 2.18 and EV/Sales of 2.69 are not excessive. The pending acquisition makes a pure valuation assessment difficult, as the stock price may not fully reflect standalone value.
As a new purchase, KVUE is not a compelling buy. Its fate is tied to an acquisition expected to close in late 2026, which limits potential upside. While it has strong brands and cash flow (TTM FCF $1.72B), its modest growth (3.2% Q4 revenue growth) and fair forward P/E of 14.24 offer limited standalone appeal. It is better suited for existing shareholders to hold for the deal closure.
KVUE is primarily a short-to-medium term, event-driven investment tied to its acquisition closing in the second half of 2026. It is not suitable for long-term growth investing due to its modest organic growth trajectory. The stock's low beta (0.47) and defensive business make it a potential short-term holding for risk-averse investors awaiting the deal outcome, but not for building a long-term portfolio.